Disseminated tumor cells: Diagnosis, prognostic value, phenotyping and therapeutic strategy;Disseminierte tumorzellen: Diagnostik, prognostische relevanz, phänotypisierung und therapeutische strategien

Chirurg

Volumn 68, Issue 12, 1997, Pages 1241-1250

  Pantel, K ^a   Von Knebel Doeberitz, M ^b   Izbicki, J R ^c   Riethmuller G ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF HAMBURG   (Germany)

Author keywords

Blood; Bone marrow; Carcinomas; Immunocytochemistry; Lymph nodes; Minimal residual cancer; Polymerase chain reaction

Indexed keywords

CANCER ANTIBODY; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; HUMAN; METASTASIS; MINIMAL RESIDUAL DISEASE; MULTIMODALITY CANCER THERAPY; PHENOTYPE; POLYMERASE CHAIN REACTION; PROGNOSIS; REVIEW; TUMOR EMBOLISM;

ANTIBODIES, NEOPLASM; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; HUMANS; NEOPLASM CIRCULATING CELLS; NEOPLASM METASTASIS; NEOPLASM, RESIDUAL; PHENOTYPE; POLYMERASE CHAIN REACTION; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0031296951     PISSN: 00094722     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001040050351     Document Type: Review

References (65)

1. Bogard WC jr., Dean RT, Deo Y, et al (1989) Practical considerations in the production, purification, and formulation of monoclonal antibodies for immunscintigraphy and immunotherapy. Semin Nucl Med 19:202
2. Bonnheim DC, Petrelli NJ, Herrera L, et al (1986) Osseus metastases from colorectal carcinoma. Am J Surg 151:457
3. Burkhardt R, Frisch B, Kettner G (1980) The clinical study of micrometastatic cancer by bone biopsy. Bull Cancer 67:291
4. Connors TA (1996) Is there a future for cancer chemotherapy. Ann Oncol 7:445
5. Cote RJ, Beattie EJ, Chaiwun B, et al (1995) Detection of occult bone marow micrometastases in patients with operable lung carciönoma. Ann Surg 222:415
6. Cote RJ, Rosen PP, Lesser ML, et al (1991) Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol 9:1749
7. Denis MG, Tessier M-H, Dréno B, et al (1996) Circulating micrometastases following oncological surgery. Lancet 347:913
8. Diel IJ, Kaufmann M, Costa SD, et al (1996) Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst 88:1652
9. Dillman RO (1994) Antibodies as cytotoxic therapy. J Clin Oncol 12:1497
10. Eschwège P, Dumas F, Blanchet P, et al (1995) Haematogenous dissemination of prostatic epithelial cells during radical prostatectomy. Lancet 346:1528
11. Haller DG (1995) An overview of adjuvant therapy for colorectal cancer. Eur J Cancer 31A: 1255
12. Hämmerling G, Maschek V, Sturmhöfel K, et al (1989) Regulation and functional role of MHC expression on tumors. In: Melchers F (ed) Progress Immunology. Springer, Berlin Heidelberg New York, p 1071
13. Hansen E, Wolff N, Knuechel R, et al (1995) Tumor cells in blood shed from the surgical field. Arch Surg 130:387
14. Harbeck N, Untch M, Pache L, et al (1994) Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up. Br J Cancer 69: 566
15. Hayashi N, Ito I, Yanagisawa A, et al (1995) Genetic diagnosis of lymph-node metastasis in colorectal cancer. Lancet 345:1257
16. Heiss MM, Allgayer H, Gruetzner KU, et al (1995) Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer. Nat Med 1:1035
17. Hermanek P jr. (1994) What's new in TNM. Pathol Res Pract 190: 97
18. Hoechtlen-Vollmar W, Gruber R, Bodenmüller H, et al (1997) Occult epithelial tumor cells detected in bone marrow by an enzyme immunoassay specific for cytokeratin-19. Int J Cancer 70: 396
19. Izbicki JR, Hosch SB, Pichlmeier U (1996) Prognostic significance of immunhistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. N Engl J Med 337:1188
20. Jain RK (1990) Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 50:2741
21. Jauch KW, Heiss MM, Cruekner U (1996) Prognostic significance of bone marrow micrometastases in patients with gastric cancer. J Clin Oncol 14:1810
22. Klein-Bauernschmidt P, von Knebel Doeberitz M, Ehrbar M, et al (1996) Improved efficacy of chemotherapy by parvovirus-mediated sensitization of human tumour cells. Eur J Cancer 32A: 1774
23. Koehler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495
24. Krismann M, Todt B, Schröder J, et al (1995) Low specificity of cytokeratin 19 reverse transcriptase-polymerase chain reaction analyses for detection of hematogenous lung cancer dissemination. J Clin Oncol 13: 2769
25. Lehnert M (1996) Clinical multidrug resistance in cancer: a multifactorial problem. Eur J Cancer 32A: 912
26. Lindemann F, Schlimok G, Dirschedl P, et al (1992) Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients. Lancet 340: 685
27. Mansi JL, Easton D, Berger U, et al (1991) Bone marrow micrometastases in primary breast cancer: prognostic significance after 6 years' follow-up. Eur J Cancer 27: 1552
28. McNeil C (1995) A new generation of monoclonal antibodies arrives at the clinic. J Natl Cancer Inst 87: 558
29. Monson J, Pazdur R (1996) Adjuvant therapy for colorectal cancer. Inpharma [Suppl] 4: 3
30. Müller P, Weckermann D, Riethmüller G, et al (1996) Detection of genetic alterations in micrometastatic cells in bone marrow of cancer patients by fluorescence in situ hybridization. Cancer Genet Cytogenet 88: 8
31. Naume B, Borgen E, Beiske K, et al (1997) Detection of isolated breast carcinoma cells in peripheral blood or bone marrow by immunomagnetic techniques. J Hematother 6: 103
32. Neumaier M, Gerhard M, Wagener C (1995) Diagnosis of micrometastases by the amplification of tissue-specific genes. Gene 159: 43
33. Osborne MP, Rosen PP (1994) Detection and management of bone marrow micrometastases in breast cancer. Oncology 8: 25
34. Pantel K, Dickmanns A, Zippelius A, et al (1995) Establishment of micrometastatic carcinoma cell lines: a novel source of tumor cell vaccines. J Natl Cancer Inst 87: 1162
35. Pantel K, Enzmann T, Kollermann J, et al (1997) Immunocytochemical monitoring of micrometastatic disease: reduction of prostate cancer cells in bone marrow by androgen deprivation. Int J Cancer 71: 521
36. Pantel K, Izbicki J, Passlick B, et al (1996) Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases. Lancet 347: 649
37. Pantel K, Riethmüller G (1996) Micrometastasis detection and treatment with monoclonal antibodies. In: Günthert U, Schlag PM, Birchmeier W (eds) Attempts to understand metastasis formation III. Springer, Berlin Heidelberg New York, p 1
38. Pantel K, Schlimok G, Angstwurm M, et al (1994) Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow. J Hematother 3:165
39. Pantel K, Schlimok G, Braun S, et al (1993) Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 85: 1419
40. Pardoll DM (1993) Cancer vaccines. Immunol Today 14: 310
41. Passlick B, Izbicki JR, Kubuschok B, et al (1994) Immunohistochemical assessment of individual tumor cells in lymph nodes of patients with non-small cell lung cancer. J Clin Oncol 12: 1827
42. Peters GJ, van der Wilt CL, van Triest B, et al (1995) Thymidylate synthethase and drug resistance. Eur J Cancer 31A: 1299
43. Ragnhammer P, Fagerberg J, Frödin J-E, et al (1993) Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma - long-lasting, complete remissions can be induced. Int J Cancer 53: 751
44. Riethmüller G, Holz E, Schlimok G, et al (1996) Monoclonal antibody (mab) adjuvant therapy of Dukes C colorectal carcinoma: 7-year update of as prospective randomized trial. Proc ASCO 15: 444
45. Riethmüller G, Schneider-Gädicke E, Schlimok G, et al (1994) Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes C colorectal carcinoma. Lancet 343: 1177
46. Schlimok G (1988) Mikrometastasen epithelialer Tumoren im Knochenmark: Immunzytochemischer Nachweis und in vivo Markierung mit Hilfe monoklonaler Antikörper. Ludwig-Maximilians-Universität München, Habilitationsschrift
47. Schlimok G, Funke I, Holzmann B, et al (1987) Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies. Proc Natl Acad Sci USA 84: 8672
48. Schlimok G, Funke I, Pantel K, et al (1991) Micrometastatic tumor cells in bone marrow of patients with gastric cancer: methodological aspects of detection and prognostic significance. Eur J Cancer 27: 1461
49. Schlimok G, Riethmüller G (1995) Monoclonal antibodies in the therapy of minimally residual solid tumors. Onkologie 18: 403
50. Schmoll HJ (1997) Adjuvante Therapie des kolorektalen Karzinoms - Stand der Therapiekonzepte 1997. In: Schmoll HJ, Höffken K, Possinger K (Hrsg) Kompendium Internistische Onkologie. Springer, Berlin Heidelberg New York, p 694
51. Schoeber C, Schulze M, Schlimok G, et al (1996) Open label pilot study of monoclonal antibody 17-1A in combination with 5-Fluorouracil/Levamisol or 5-FU/Folinic acid in patients with advanced colorectal cancer. Proc. ASCO 15: 229
52. Schwarz MA, Owaribe K, Kartenbeck J, et al (1990) Desmosomes and hemidesmosomes: Constitutive molecular components. Ann Rev Cell Biol 6: 461
53. Soeth E, Vogel I, Röder C, et al (1997) Comparative analysis of bone marrow and venous blood isolates from gastrointestinal cancer patients for the detection of disseminated tumor cells using reverse transcription PCR. Cancer Res. 57: 3106
54. Tada M, Omata M, Kawai SH, et al (1993) Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma. Cancer Res. 53: 2472
55. Takamuku K, Baba K, Aringa k, et al (1996) Apoptosis in antibody-dependent monocyte-mediated cytotoxicity with monoclonal antibody 17-1A against human colorectal carcinoma cells: enhancement with interferon-y. Cancer Immunol Immunother 43: 220
56. Talbot RW, Irvine B, Jass JR, et al (1989) Bone metastases in carcinoma of the rectum: a clinical and pathological review. Eur J Surg Oncol 15: 449
57. Thorban S, Roder JD, Nekarda H, et al (1996) Immunocytochemical detection of disseminated epithelial tumor cells in bone marrow of patients with esophageal carcinoma. J Natl Cancer Inst 88: 1222
58. Traweek ST, Liu J, Battifora H (1993) Keratin gene expression in non-epithelial tissues. Detection with polymerase chain reaction. Am J Pathol 142: 1111
59. van Triest B, van Groeningen CJ, Pinedo HM (1995) Current chemotherapeutic possibilities in the treatment of colorectal cancer. Eur J Cancer 31 A: 1193
60. von Knebel Doeberitz M, Gebert J, Herfarth Ch (1996) Der Einfluß molekularer Diagnostikverfahren auf die chirurgische Therapie maligner Erkrankungen. Chirurg 67: 967
61. Wallich R, Bulbue N, Hämmerling GJ, et al (1985) Abrogation of metastatic properties of tumor cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature 315: 301
62. Weiss L, Grundmann E, Thorhorst J, et al (1986) Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necrosies. J Pathol 150: 195
63. Weitz J, Kienle P, Lacroix J, et al (1997) Dissemination of tumor cells in patients undergoing surgery for colorectal cancer. Clin Cancer Res (submitted)
64. Welch JP, Donaldson GA (1979) The clinical correlation of an autopsy study of recurrent colorectal cancer. Ann Surg 189: 496
65. Zippelius A, Kufer P, Honold G, et al (1997) Limitations of reverse transcriptase-polymerase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow. J Clin Oncol 15: 2701